<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39428557</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2162-3279</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Brain and behavior</Title><ISOAbbreviation>Brain Behav</ISOAbbreviation></Journal><ArticleTitle>The Risk of Exacerbation of Myasthenia Gravis After COVID-19 Omicron Infection.</ArticleTitle><Pagination><StartPage>e70074</StartPage><MedlinePgn>e70074</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e70074</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/brb3.70074</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of this study is to ascertain whether COVID-19 Omicron infection is associated with exacerbations in these myasthenia gravis (MG) patients.</AbstractText><AbstractText Label="RESULT" NlmCategory="RESULTS">In total, 289 MG patients (comprising 60% females, with an average age of 46 ± 15 years) were enrolled. A total of 80.9% of MG patients reported a COVID-19 infection, with the majority experiencing a benign course (88%). MG patients who experienced COVID-19 infection demonstrated a higher likelihood of MG exacerbation, compared to those without the infection (18.8% vs. 7.3%, p = 0.039). In the survival analysis, after adjusting for confounding factors, the hazard ratio (HR) for exacerbation post-infection was found to be 3.38 (95% CI 1.20-9.53, p = 0.021). Compared to the exacerbation rates observed in JTA21, an increase was noted in DTM23 among COVID-19-infected MG patients (4.4% vs. 17.2%, p &lt; 0.001).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The COVID-19 is the risk of MG exacerbation.</AbstractText><CopyrightInformation>© 2024 The Author(s). Brain and Behavior published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Nana</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ziya</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Dongren</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hongxi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Hongyu</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-7637-1305</Identifier><AffiliationInfo><Affiliation>Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, PR China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>21HXFH041</GrantID><Agency>1·3·5 Project for Disciplines of Excellence-Clinical Research Incubation Project, West China Hospital, Sichuan University</Agency><Country /></Grant><Grant><GrantID>2022YFS0315</GrantID><Agency>Department of Science and Technology of Sichuan Province</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Brain Behav</MedlineTA><NlmUniqueID>101570837</NlmUniqueID></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009157" MajorTopicYN="Y">Myasthenia Gravis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID‐19</Keyword><Keyword MajorTopicYN="N">Omicron</Keyword><Keyword MajorTopicYN="N">myasthenia gravis</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>10</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>10</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>20</Day><Hour>23</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39428557</ArticleId><ArticleId IdType="pmc">PMC11491296</ArticleId><ArticleId IdType="doi">10.1002/brb3.70074</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alshekhlee, A. , Miles J. D., Katirji B., Preston D. C., and Kaminski H. J. 2009. “Incidence and Mortality Rates of Myasthenia Gravis and Myasthenic Crisis in US Hospitals.” Neurology 72, no. 18: 1548–1554. 10.1212/WNL.0b013e3181a41211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181a41211</ArticleId><ArticleId IdType="pubmed">19414721</ArticleId></ArticleIdList></Reference><Reference><Citation>Blum, S. , Lee D., Gillis D., McEniery D. F., Reddel S., and McCombe P.. 2015. “Clinical Features and Impact of Myasthenia Gravis Disease in Australian Patients.” Journal of Clinical Neuroscience 22, no. 7: 1164–1169. 10.1016/j.jocn.2015.01.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2015.01.022</ArticleId><ArticleId IdType="pubmed">26021730</ArticleId></ArticleIdList></Reference><Reference><Citation>Businaro, P. , Vaghi G., Marchioni E., et al. 2021. “COVID‐19 in Patients With Myasthenia Gravis: Epidemiology and Disease Course.” Muscle &amp; Nerve 64, no. 2: 206–211. 10.1002/mus.27324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27324</ArticleId><ArticleId IdType="pmc">PMC8242475</ArticleId><ArticleId IdType="pubmed">34031902</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung, P. H. , Chan C. P., and Jin D. Y.. 2022. “Lessons Learned From the Fifth Wave of COVID‐19 in Hong Kong in Early 2022.” Emerg Microbes Infect 11, no. 1: 1072–1078. 10.1080/22221751.2022.2060137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2060137</ArticleId><ArticleId IdType="pmc">PMC9004509</ArticleId><ArticleId IdType="pubmed">35348429</ArticleId></ArticleIdList></Reference><Reference><Citation>
COVID‐19 Clinical and Surveillance Data—December 9, 2022 to April 27, 2023, China
. n.d. https://weekly.chinacdc.cn/news/covid‐surveillance/0ede7663‐6dc7‐4638‐8867‐2708f60a46bf_en.htm.</Citation></Reference><Reference><Citation>de León, A. M. , Aban I., McPherson T., et al. 2023. “Impact of the COVID‐19 Pandemic on Patients With Myasthenia Gravis: A Survey of the Myasthenia Gravis Foundation of America MG Patient Registry.” Muscle &amp; Nerve 67, no. 1: 25–32. 10.1002/mus.27743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27743</ArticleId><ArticleId IdType="pmc">PMC9877793</ArticleId><ArticleId IdType="pubmed">36324261</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewanjee, S. , Vallamkondu J., Kalra R. S., Puvvada N., Kandimalla R., and Reddy P. H.. 2021. “Emerging COVID‐19 Neurological Manifestations: Present Outlook and Potential Neurological Challenges in COVID‐19 Pandemic.” Molecular Neurobiology 58, no. 9: 4694–4715. 10.1007/s12035-021-02450-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-021-02450-6</ArticleId><ArticleId IdType="pmc">PMC8224263</ArticleId><ArticleId IdType="pubmed">34169443</ArticleId></ArticleIdList></Reference><Reference><Citation>Farina, A. , Falso S., Cornacchini S., et al. 2022. “Safety and Tolerability of SARS‐Cov‐2 Vaccination in Patients With Myasthenia Gravis: A Multicenter Experience.” European Journal of Neurology 29, no. 8: 2505–2510. 10.1111/ene.15348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15348</ArticleId><ArticleId IdType="pmc">PMC9111609</ArticleId><ArticleId IdType="pubmed">35390184</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu, D. , He G., Li H., et al. 2023. “Effectiveness of COVID‐19 Vaccination Against SARS‐CoV‐2 Omicron Variant Infection and Symptoms—China, December 2022–February 2023[J].” China CDC Weekly 5, no. 17: 369–373. 10.46234/ccdcw2023.070.</Citation><ArticleIdList><ArticleId IdType="doi">10.46234/ccdcw2023.070</ArticleId><ArticleId IdType="pmc">PMC10184382</ArticleId><ArticleId IdType="pubmed">37197449</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao, B. , He L., Bao Y., et al. 2023. “Repeated Vaccination of Inactivated SARS‐CoV‐2 Vaccine Dampens Neutralizing Antibodies Against Omicron Variants in Breakthrough Infection.” Cell Research 33, no. 3: 258–261. 10.1038/s41422-023-00781-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-023-00781-8</ArticleId><ArticleId IdType="pmc">PMC9875169</ArticleId><ArticleId IdType="pubmed">36697703</ArticleId></ArticleIdList></Reference><Reference><Citation>Garibaldi, M. , Siciliano G., and Antonini G.. 2021. “Telemedicine for Neuromuscular Disorders During the COVID‐19 Outbreak.” Journal of Neurology 268, no. 1: 1–4. 10.1007/s00415-020-10063-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10063-7</ArticleId><ArticleId IdType="pmc">PMC7348562</ArticleId><ArticleId IdType="pubmed">32651671</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilhus, N. E. 2016. “Myasthenia Gravis.” New England Journal of Medicine 375, no. 26: 2570–2581. 10.1056/NEJMra1602678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1602678</ArticleId><ArticleId IdType="pubmed">28029925</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilhus, N. E. 2023. “Myasthenia Gravis, Respiratory Function, and Respiratory Tract Disease.” Journal of Neurology 270: 3329—3320. 10.1007/s00415-023-11733-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-023-11733-y</ArticleId><ArticleId IdType="pmc">PMC10132430</ArticleId><ArticleId IdType="pubmed">37101094</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilhus, N. E. , Romi F., Hong Y., and Skeie G. O. 2018. “Myasthenia Gravis and Infectious Disease.” Journal of Neurology 265, no. 6: 1251–1258. 10.1007/s00415-018-8751-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-8751-9</ArticleId><ArticleId IdType="pubmed">29372387</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilhus, N. E. , Tzartos S., Evoli A., Palace J., Burns T. M., and Verschuuren J.. 2019. “Myasthenia Gravis.” Nature Reviews Disease Primers 5, no. 1: 30. 10.1038/s41572-019-0079-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-019-0079-y</ArticleId><ArticleId IdType="pubmed">31048702</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidon, A. C. , and Amato A. A.. 2020. “COVID‐19 and Neuromuscular Disorders.” Neurology 94, no. 22: 959–969. 10.1212/WNL.0000000000009566.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000009566</ArticleId><ArticleId IdType="pubmed">32284362</ArticleId></ArticleIdList></Reference><Reference><Citation>Huan, X. , Chen J., Zhong H., et al. 2024. “Clinical Outcome and Peripheral Immune Profile of Myasthenic Crisis With Omicron Infections: A Prospective Cohort Study.” Clinical Immunology 259: 109879. 10.1016/j.clim.2023.109879.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2023.109879</ArticleId><ArticleId IdType="pubmed">38142901</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasa, K. , Yoshikawa H., Hamaguchi T., et al. 2018. “Time‐Series Analysis: Variation of Anti‐Acetylcholine Receptor Antibody Titer in Myasthenia Gravis Is Related to Incidence of Mycoplasma pneumoniae and Influenza Virus Infections.” Neurological Research 40, no. 2: 102–109. 10.1080/01616412.2017.1407021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01616412.2017.1407021</ArticleId><ArticleId IdType="pubmed">29173125</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakubíková, M. , Týblová M., Tesař A., et al. 2021. “Predictive Factors for a Severe Course of COVID‐19 Infection in Myasthenia Gravis Patients With an Overall Impact on Myasthenic Outcome Status and Survival.” European Journal of Neurology 28, no. 10: 3418–3425. 10.1111/ene.14951.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14951</ArticleId><ArticleId IdType="pmc">PMC8239548</ArticleId><ArticleId IdType="pubmed">34080271</ArticleId></ArticleIdList></Reference><Reference><Citation>Karimi, N. , Fatehi F., Okhovat A. A., et al. 2022. “Clinical Features and Outcomes of Patients With Myasthenia Gravis Affected by COVID‐19: A Single‐Center Study.” Clinical Neurology and Neurosurgery 222: 107441. 10.1016/j.clineuro.2022.107441.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clineuro.2022.107441</ArticleId><ArticleId IdType="pubmed">36174408</ArticleId></ArticleIdList></Reference><Reference><Citation>Kassardjian, C. D. , Widdifield J., Paterson J. M., et al. 2020. “Serious Infections in Patients With Myasthenia Gravis: Population‐Based Cohort Study.” European Journal of Neurology 27, no. 4: 702–708. 10.1111/ene.14153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14153</ArticleId><ArticleId IdType="pubmed">31997519</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong, L. , Wang X., Chen H., et al. 2022. “Relapses After SARS‐CoV‐2 Vaccination in Patients With Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis.” Multiple Sclerosis and Related Disorders 68: 104167. 10.1016/j.msard.2022.104167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2022.104167</ArticleId><ArticleId IdType="pmc">PMC9472679</ArticleId><ArticleId IdType="pubmed">36170773</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopańska, M. , Batoryna M., Bartman P., Szczygielski J., and Banaś‐Ząbczyk A.. 2022. “Disorders of the Cholinergic System in COVID‐19 Era—A Review of the Latest Research.” International Journal of Molecular Sciences 23, no. 2: 672. 10.3390/ijms23020672.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23020672</ArticleId><ArticleId IdType="pmc">PMC8775685</ArticleId><ArticleId IdType="pubmed">35054856</ArticleId></ArticleIdList></Reference><Reference><Citation>Leiner, J. , Pellissier V., Hohenstein S., et al. 2022. “Characteristics and Outcomes of COVID‐19 Patients During B.1.1.529 (Omicron) Dominance Compared to B.1.617.2 (Delta) in 89 German Hospitals.” BMC Infectious Diseases 22, no. 1: 802. 10.1186/s12879-022-07781-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07781-w</ArticleId><ArticleId IdType="pmc">PMC9610359</ArticleId><ArticleId IdType="pubmed">36303111</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, H. Y. , Shao L. Y., Song M., Hu S. M., Yue Y. X., and Li H. F. 2022. “Safety of Inactivated SARS‐CoV‐2 Vaccines in Myasthenia Gravis: A Survey‐Based Study.” Frontiers in Immunology 13: 923017. 10.3389/fimmu.2022.923017.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.923017</ArticleId><ArticleId IdType="pmc">PMC9388926</ArticleId><ArticleId IdType="pubmed">35990671</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, X. , Raventós B., Roel E., et al. 2022. “Association Between Covid‐19 Vaccination, SARS‐CoV‐2 Infection, and Risk of Immune Mediated Neurological Events: Population Based Cohort and Self‐Controlled Case Series Analysis.” Bmj 376: e068373. 10.1136/bmj-2021-068373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-068373</ArticleId><ArticleId IdType="pmc">PMC8924704</ArticleId><ArticleId IdType="pubmed">35296468</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, Y. , Ji D., Cai W., et al. 2021. “Clinical Characteristics, Cause Analysis and Infectivity of COVID‐19 Nucleic Acid Repositive Patients: A Literature Review.” Journal of Medical Virology 93, no. 3: 1288–1295. 10.1002/jmv.26491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26491</ArticleId><ArticleId IdType="pmc">PMC7894340</ArticleId><ArticleId IdType="pubmed">32890414</ArticleId></ArticleIdList></Reference><Reference><Citation>Madhi, S. A. , Kwatra G., Myers J. E., et al. 2022. “Population Immunity and Covid‐19 Severity With Omicron Variant in South Africa.” New England Journal of Medicine 386, no. 14: 1314–1326. 10.1056/NEJMoa2119658.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2119658</ArticleId><ArticleId IdType="pmc">PMC8908853</ArticleId><ArticleId IdType="pubmed">35196424</ArticleId></ArticleIdList></Reference><Reference><Citation>Meo, S. A. , Meo A. S., Al‐Jassir F. F., and Klonoff D. C.. 2021. “Omicron SARS‐CoV‐2 New Variant: Global Prevalence and Biological and Clinical Characteristics.” European Review for Medical and Pharmacological Sciences 25, no. 24: 8012–8018. 10.26355/eurrev_202112_27652.</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202112_27652</ArticleId><ArticleId IdType="pubmed">34982465</ArticleId></ArticleIdList></Reference><Reference><Citation>Muppidi, S. , Guptill J. T., Jacob S., et al. 2020. “COVID‐19‐Associated Risks and Effects in Myasthenia Gravis (CARE‐MG).” Lancet Neurology 19, no. 12: 970–971. 10.1016/S1474-4422(20)30413-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30413-0</ArticleId><ArticleId IdType="pmc">PMC7837033</ArticleId><ArticleId IdType="pubmed">33212055</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelke, C. , Stascheit F., Eckert C., et al. 2022. “Independent Risk Factors for Myasthenic Crisis and Disease Exacerbation in a Retrospective Cohort of Myasthenia Gravis Patients.” Journal of Neuroinflammation 19, no. 1: 89. 10.1186/s12974-022-02448-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-022-02448-4</ArticleId><ArticleId IdType="pmc">PMC9005160</ArticleId><ArticleId IdType="pubmed">35413850</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan, Y. , Zhang D., Yang P., Poon L. L. M., and Wang Q.. 2020. “Viral Load of SARS‐CoV‐2 in Clinical Samples.” Lancet Infectious Diseases 20, no. 4: 411–412. 10.1016/S1473-3099(20)30113-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30113-4</ArticleId><ArticleId IdType="pmc">PMC7128099</ArticleId><ArticleId IdType="pubmed">32105638</ArticleId></ArticleIdList></Reference><Reference><Citation>Pscheidt, V. M. , Gregianini T. S., Martins L. G., and Veiga A.. 2021. “Epidemiology of Human Adenovirus Associated With Respiratory Infection in Southern Brazil.” Reviews in Medical Virology 31, no. 4: e2189. 10.1002/rmv.2189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2189</ArticleId><ArticleId IdType="pubmed">33156553</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramasamy, S. , and Subbian S.. 2021. “Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID‐19 Pathogenesis.” Clinical Microbiology Reviews 34, no. 4: e0016321. [published correction appears in 10.1128/CMR.00163-21].</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00163-21</ArticleId><ArticleId IdType="pmc">PMC8142516</ArticleId><ArticleId IdType="pubmed">33980688</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos‐Fransi, A. , Rojas‐García R., Segovia S., et al. 2015. “Myasthenia Gravis: Descriptive Analysis of Life‐Threatening Events in a Recent Nationwide Registry.” European Journal of Neurology 22, no. 7: 1056–1061. 10.1111/ene.12703.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12703</ArticleId><ArticleId IdType="pubmed">25847221</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricciardi, D. , Casagrande S., Iodice F., et al. 2021. “Myasthenia Gravis and Telemedicine: A Lesson From COVID‐19 Pandemic.” Neurological Sciences 42, no. 12: 4889–4892. 10.1007/s10072-021-05566-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-021-05566-8</ArticleId><ArticleId IdType="pmc">PMC8390022</ArticleId><ArticleId IdType="pubmed">34436726</ArticleId></ArticleIdList></Reference><Reference><Citation>Salik, I. , Rodhouse H. B., and Barst S.. 2020. “Myasthenic Crisis in the Setting of Coronavirus Disease 2019 (COVID‐19).” Journal of Clinical Anesthesia 67: 110001. 10.1016/j.jclinane.2020.110001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinane.2020.110001</ArticleId><ArticleId IdType="pmc">PMC7368911</ArticleId><ArticleId IdType="pubmed">32707518</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultheiß, C. , Willscher E., Paschold L., et al. 2022. “The IL‐1β, IL‐6, and TNF Cytokine Triad Is Associated With Post‐Acute Sequelae of COVID‐19.” Cell Reports Medicine 3, no. 6: 100663. 10.1016/j.xcrm.2022.100663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100663</ArticleId><ArticleId IdType="pmc">PMC9214726</ArticleId><ArticleId IdType="pubmed">35732153</ArticleId></ArticleIdList></Reference><Reference><Citation>Seok, H. Y. , Shin H. Y., Kim J. K., et al. 2017. “The Impacts of Influenza Infection and Vaccination on Exacerbation of Myasthenia Gravis.” Journal of Clinical Neurology 13, no. 4: 325–330. 10.3988/jcn.2017.13.4.325.</Citation><ArticleIdList><ArticleId IdType="doi">10.3988/jcn.2017.13.4.325</ArticleId><ArticleId IdType="pmc">PMC5653619</ArticleId><ArticleId IdType="pubmed">29057629</ArticleId></ArticleIdList></Reference><Reference><Citation>Solé, G. , Mathis S., Friedman D., et al. 2021. “Impact of Coronavirus Disease 2019 in a French Cohort of Myasthenia Gravis.” Neurology 96, no. 16: e2109–e2120. 10.1212/WNL.0000000000011669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000011669</ArticleId><ArticleId IdType="pubmed">33568541</ArticleId></ArticleIdList></Reference><Reference><Citation>Stascheit, F. , Grittner U., Hoffmann S., et al. 2023. “Risk and Course of COVID‐19 in Immunosuppressed Patients With Myasthenia Gravis.” Journal of Neurology 270, no. 1: 1–12. 10.1007/s00415-022-11389-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-022-11389-0</ArticleId><ArticleId IdType="pmc">PMC9512984</ArticleId><ArticleId IdType="pubmed">36166068</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang, K. T. , Hsu B. C., and Chen D. Y.. 2021. “Autoimmune and Rheumatic Manifestations Associated with COVID‐19 in Adults: An Updated Systematic Review.” Frontiers in Immunology 12: 645013. 10.3389/fimmu.2021.645013.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.645013</ArticleId><ArticleId IdType="pmc">PMC7994612</ArticleId><ArticleId IdType="pubmed">33777042</ArticleId></ArticleIdList></Reference><Reference><Citation>To, K. K. , Sridhar S., Chiu K. H., et al. 2021. “Lessons Learned 1 Year After SARS‐CoV‐2 Emergence Leading to COVID‐19 Pandemic.” Emerg Microbes Infect 10, no. 1: 507–535. 10.1080/22221751.2021.1898291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.1898291</ArticleId><ArticleId IdType="pmc">PMC8006950</ArticleId><ArticleId IdType="pubmed">33666147</ArticleId></ArticleIdList></Reference><Reference><Citation>Tüzün, E. , Huda R., and Christadoss P. 2011. “Complement and Cytokine Based Therapeutic Strategies in Myasthenia Gravis.” Journal of Autoimmunity 37, no. 2: 136–143. 10.1016/j.jaut.2011.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2011.05.006</ArticleId><ArticleId IdType="pubmed">21636248</ArticleId></ArticleIdList></Reference><Reference><Citation>Verschuuren, J. J. , Palace J., Murai H., Tannemaat M. R., Kaminski H. J., and Bril V.. 2022. “Advances and Ongoing Research in the Treatment of Autoimmune Neuromuscular Junction Disorders.” Lancet Neurology 21, no. 2: 189–202. 10.1016/S1474-4422(21)00463-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00463-4</ArticleId><ArticleId IdType="pubmed">35065041</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, N. , Wang C., Huang J., et al. 2022. “Clinical and Pulmonary CT Characteristics of Patients Infected With the SARS‐CoV‐2 Omicron Variant Compared With Those of Patients Infected With the Alpha Viral Strain.” Front Public Health 10: 931480. 10.3389/fpubh.2022.931480.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.931480</ArticleId><ArticleId IdType="pmc">PMC9315283</ArticleId><ArticleId IdType="pubmed">35903393</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, W. , Yang S., Wang L., et al. 2022. “Clinical Characteristics of 310 SARS‐CoV‐2 Omicron Variant Patients and Comparison With Delta and Beta Variant Patients in China.” Virol Sin 37, no. 5: 704–715. 10.1016/j.virs.2022.07.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virs.2022.07.014</ArticleId><ArticleId IdType="pmc">PMC9357284</ArticleId><ArticleId IdType="pubmed">35948265</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, X. , Zhang W., and Chen S.. 2022. “Shanghai's Life‐Saving Efforts Against the Current Omicron Wave of the COVID‐19 Pandemic.” Lancet 399, no. 10340: 2011–2012. 10.1016/S0140-6736(22)00838-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00838-8</ArticleId><ArticleId IdType="pmc">PMC9075855</ArticleId><ArticleId IdType="pubmed">35533708</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>